Lastly, Zucchinetti et al. analyzed a cohort of 41 patients with r/r LBCL treated with Glofitamab and performed CAPP sequencing of circulating tumor DNA (ctDNA), demonstrating that more than 21% of r/r LBCL presented with TP53 (44%), KMT2D, PIM1 and IGLL5 (37% each), CARD11 (27%), HIST1H1E and CREBBP (24% each), or BCL2 (22%) mutations [107]. The gene discussed is TP53; the disease is neoplasm.